Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4755,DB01033,Mercaptopurine
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4756,DB01033,Mercaptopurine
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4757,DB01033,Mercaptopurine
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4758,DB01033,Mercaptopurine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4759,DB01033,Mercaptopurine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4760,DB01033,Mercaptopurine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4761,DB01033,Mercaptopurine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4762,DB01033,Mercaptopurine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4763,DB01033,Mercaptopurine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4764,DB01033,Mercaptopurine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4765,DB01033,Mercaptopurine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4766,DB01033,Mercaptopurine
,3957504,half-time of elimination for the first rapid phase (t1/2 alpha),The mean half-time of elimination for the first rapid phase (t1/2 alpha) was 6.1 min (S.D. +/- 4.1) and for the terminal phase (t1/2 beta) 50 min (+/- 31).,Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,6.1,9252,DB01033,Mercaptopurine
,3957504,terminal phase (t1/2 beta),The mean half-time of elimination for the first rapid phase (t1/2 alpha) was 6.1 min (S.D. +/- 4.1) and for the terminal phase (t1/2 beta) 50 min (+/- 31).,Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,50,9253,DB01033,Mercaptopurine
,3957504,total plasma clearance (Cl),The total plasma clearance (Cl) was 6.9 1./min (+/- 3.0).,Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),[1] / [min],6.9,9254,DB01033,Mercaptopurine
,3957504,t1/2 alpha,"The mean t1/2 alpha was 4.6 min (+/- 2.2), t1/2 beta 74 min (+/- 58) and Cl 8.0 1./min (+/- 5.8).",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,4.6,9255,DB01033,Mercaptopurine
,3957504,t1/2 beta,"The mean t1/2 alpha was 4.6 min (+/- 2.2), t1/2 beta 74 min (+/- 58) and Cl 8.0 1./min (+/- 5.8).",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,74,9256,DB01033,Mercaptopurine
,3957504,Cl,"The mean t1/2 alpha was 4.6 min (+/- 2.2), t1/2 beta 74 min (+/- 58) and Cl 8.0 1./min (+/- 5.8).",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),[1] / [min],8.0,9257,DB01033,Mercaptopurine
,3957504,minimum effective concentration,"We also studied inhibition of Leucoagglutin (LA) stimulated lymphocyte proliferation by patient plasma at different times in six of the patients following AZA i.v. Sera drawn at 5, 10 and 30 min significantly inhibited the LA-induced proliferation, with an estimated minimum effective concentration of 6-MP in the cultures of about 0.02-0.04 microM.",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),μM,0.02-0.04,9258,DB01033,Mercaptopurine
,15167634,half-life,"Steady-state concentrations were reached after 4 weeks, indicating a half-life of approximately 5 days for both 6-TGN and 6-MMPR; the concentrations were 368 (CI95% 284-452) and 2837 (CI95% 2101-3573) pmol/8 x 10 RBCs, respectively.",Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),d,5,13561,DB01033,Mercaptopurine
,15167634,half-life,"Steady-state concentrations were reached after 4 weeks, indicating a half-life of approximately 5 days for both 6-TGN and 6-MMPR; the concentrations were 368 (CI95% 284-452) and 2837 (CI95% 2101-3573) pmol/8 x 10 RBCs, respectively.",Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),[pM] / [8],368,13562,DB01033,Mercaptopurine
,15167634,half-life,"Steady-state concentrations were reached after 4 weeks, indicating a half-life of approximately 5 days for both 6-TGN and 6-MMPR; the concentrations were 368 (CI95% 284-452) and 2837 (CI95% 2101-3573) pmol/8 x 10 RBCs, respectively.",Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),[pM] / [8],2837,13563,DB01033,Mercaptopurine
less,15167634,ratio,A 6-MMPR/6-TGN ratio less than 11 was associated with therapeutic efficacy.,Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167634/),,11,13564,DB01033,Mercaptopurine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,34.4,16171,DB01033,Mercaptopurine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,23.4,16172,DB01033,Mercaptopurine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,17.0,16173,DB01033,Mercaptopurine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.046,16174,DB01033,Mercaptopurine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.068,16175,DB01033,Mercaptopurine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.084,16176,DB01033,Mercaptopurine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],0.79,16177,DB01033,Mercaptopurine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.45,16178,DB01033,Mercaptopurine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.84,16179,DB01033,Mercaptopurine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],407.6,16180,DB01033,Mercaptopurine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],251.0,16181,DB01033,Mercaptopurine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],180.7,16182,DB01033,Mercaptopurine
,3153216,peak plasma concentration,After dose normalization the mean peak plasma concentration was 0.68 microM (range 0.12-1.38) and the area under the plasma concentration-time curve (AUC) was 1.37 microM.h (range 0.12-3.04).,Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153216/),μM,0.68,19881,DB01033,Mercaptopurine
,3153216,area under the plasma concentration-time curve (AUC),After dose normalization the mean peak plasma concentration was 0.68 microM (range 0.12-1.38) and the area under the plasma concentration-time curve (AUC) was 1.37 microM.h (range 0.12-3.04).,Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153216/),h·μM,1.37,19882,DB01033,Mercaptopurine
,3153216,time taken to reach the peak concentration,"The mean time taken to reach the peak concentration was 1.3 h (range 1-2), and the half-life of elimination was 1.8 h (range 0.6-2.5).",Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153216/),h,1.3,19883,DB01033,Mercaptopurine
,3153216,half-life of elimination,"The mean time taken to reach the peak concentration was 1.3 h (range 1-2), and the half-life of elimination was 1.8 h (range 0.6-2.5).",Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153216/),h,1.8,19884,DB01033,Mercaptopurine
,3153216,half-life of elimination,The mean half-life of elimination from erythrocytes was 2.0 h (range 0.7-2.8).,Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153216/),h,2.0,19885,DB01033,Mercaptopurine
,33172550,peak concentration,"In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours).",[Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33172550/),[ng] / [ml],348.2,22644,DB01033,Mercaptopurine
,33172550,time to peak,"In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours).",[Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33172550/),h,48,22645,DB01033,Mercaptopurine
,33172550,half life,"In the PEG-rhG-CSF group, the peak concentration of PEG-rhG-CSF was 348.2 ng/mL (range 114.7-552.0 ng/mL), the time to peak was 48 hours (range 12-72 hours), and the half life was 14.1 hours (range 11.1-18.1 hours).",[Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33172550/),h,14.1,22646,DB01033,Mercaptopurine
,2586358,Elimination T1/2,"Elimination T1/2 was between 1.34 and 5 hours (mean 2.16 +/- 0.23 hr, mean +/- SE).",Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2586358/),h,2.16,22653,DB01033,Mercaptopurine
,2586358,AUC,"There was a significantly larger AUC of 6MP achieved by a standardized dose in longer therapy (greater than 15 mo) vs. short therapy (less than 12 mo) (462 +/- 75 and 246 +/- 58 ng.ml-1.min.mg-1.m2, P less than 0.025).",Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2586358/),[m2·min·ng] / [mg·ml],462,22654,DB01033,Mercaptopurine
,2586358,AUC,"There was a significantly larger AUC of 6MP achieved by a standardized dose in longer therapy (greater than 15 mo) vs. short therapy (less than 12 mo) (462 +/- 75 and 246 +/- 58 ng.ml-1.min.mg-1.m2, P less than 0.025).",Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2586358/),[m2·min·ng] / [mg·ml],246,22655,DB01033,Mercaptopurine
,30835935,plasma MTX,"Moderately delayed MTX elimination was defined as 42-hour plasma MTX ≥ 4.0-9.9 μM, and severely delayed elimination was defined as 42-hour plasma MTX ≥ 10 μM.",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),h,42,23549,DB01033,Mercaptopurine
≥,30835935,plasma MTX,"Moderately delayed MTX elimination was defined as 42-hour plasma MTX ≥ 4.0-9.9 μM, and severely delayed elimination was defined as 42-hour plasma MTX ≥ 10 μM.",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),μM,4.0-9.9,23550,DB01033,Mercaptopurine
≥,30835935,plasma MTX,"Moderately delayed MTX elimination was defined as 42-hour plasma MTX ≥ 4.0-9.9 μM, and severely delayed elimination was defined as 42-hour plasma MTX ≥ 10 μM.",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),μM,10,23551,DB01033,Mercaptopurine
,30835935,MTX,"Median 42-hour plasma MTX was 0.61 μM (interquartile range, 0.4-1.06 μM).",Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30835935/),μM,0.61,23552,DB01033,Mercaptopurine
,16563975,C0,This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml).,Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563975/),[ng] / [ml],6.6,24661,DB01033,Mercaptopurine
,6543392,total distribution volume (VD),"6-MP total distribution volume (VD) increased from 26.4 ml in 2 week old animals to 60.2 ml and 55.5 ml in 4-week-old and adult rats, respectively.",[Pharmacokinetics of 6-mercaptopurine in rats during postnatal development]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543392/),ml,26.4,30819,DB01033,Mercaptopurine
,6543392,total distribution volume (VD),"6-MP total distribution volume (VD) increased from 26.4 ml in 2 week old animals to 60.2 ml and 55.5 ml in 4-week-old and adult rats, respectively.",[Pharmacokinetics of 6-mercaptopurine in rats during postnatal development]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543392/),ml,60.2,30820,DB01033,Mercaptopurine
,6543392,total distribution volume (VD),"6-MP total distribution volume (VD) increased from 26.4 ml in 2 week old animals to 60.2 ml and 55.5 ml in 4-week-old and adult rats, respectively.",[Pharmacokinetics of 6-mercaptopurine in rats during postnatal development]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543392/),ml,55.5,30821,DB01033,Mercaptopurine
,6543392,relative volume of distribution (delta,"However, the relative volume of distribution (delta, per cent of body weight) decreased from 1019 ml/kg in 2 week old rats to 317 ml/kg in adult rats.",[Pharmacokinetics of 6-mercaptopurine in rats during postnatal development]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543392/),[ml] / [kg],1019,30822,DB01033,Mercaptopurine
,6543392,relative volume of distribution (delta,"However, the relative volume of distribution (delta, per cent of body weight) decreased from 1019 ml/kg in 2 week old rats to 317 ml/kg in adult rats.",[Pharmacokinetics of 6-mercaptopurine in rats during postnatal development]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543392/),[ml] / [kg],317,30823,DB01033,Mercaptopurine
,26657824,relative bioavailability,The relative bioavailability of liquid Loulla formulation compared to the reference presentation is 76% for AUC0-9 and AUC0-∞ and 80% for Cmax.,Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26657824/),%,76,31351,DB01033,Mercaptopurine
,26657824,relative bioavailability,The relative bioavailability of liquid Loulla formulation compared to the reference presentation is 76% for AUC0-9 and AUC0-∞ and 80% for Cmax.,Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26657824/),%,80,31352,DB01033,Mercaptopurine
,2239280,area under the concentration versus time curve (AUC) 0-4 hours,"The mean area under the concentration versus time curve (AUC) 0-4 hours varied slightly from the start to the end of the MT (257 and 296 ng/ml.h, respectively).",The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [h·ml],257,33584,DB01033,Mercaptopurine
,2239280,area under the concentration versus time curve (AUC) 0-4 hours,"The mean area under the concentration versus time curve (AUC) 0-4 hours varied slightly from the start to the end of the MT (257 and 296 ng/ml.h, respectively).",The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [h·ml],296,33585,DB01033,Mercaptopurine
,2239280,plasma peak concentration,The mean plasma peak concentration increased from 98 ng/ml to 195 ng/ml (p less than 0.01) during the same period.,The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [ml],98,33586,DB01033,Mercaptopurine
,2239280,plasma peak concentration,The mean plasma peak concentration increased from 98 ng/ml to 195 ng/ml (p less than 0.01) during the same period.,The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2239280/),[ng] / [ml],195,33587,DB01033,Mercaptopurine
,2595785,total clearance,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ml] / [h·kg],379,35683,DB01033,Mercaptopurine
,2595785,volume of distribution,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[l] / [kg],1.4,35684,DB01033,Mercaptopurine
,2595785,plasma half-life,The mean plasma half-life was 2.7 +/- 1.1 hr.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),h,2.7,35685,DB01033,Mercaptopurine
,2595785,peak concentration,"When normalized to a 1 mg dose of methylprednisolone, the mean peak concentration at 1 hr was 10.0 +/- 3.5 ng/ml with an 8 hr concentration ranging from 0.3 to 5.5 ng/ml.",Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ng] / [ml],10.0,35686,DB01033,Mercaptopurine
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,0.54,40620,DB01033,Mercaptopurine
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,2.1,40621,DB01033,Mercaptopurine
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,0.74,40622,DB01033,Mercaptopurine
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,3.7,40623,DB01033,Mercaptopurine
,6580097,plasma AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],121,40624,DB01033,Mercaptopurine
,6580097,plasma AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],391,40625,DB01033,Mercaptopurine
,6580097,AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],142,40626,DB01033,Mercaptopurine
,6580097,AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],716,40627,DB01033,Mercaptopurine
,3832014,Half-life time,Half-life time of 6-MP formation in blood from AZA at e.g. 37 degrees C was equal to 28.9 +/- 2.8 min.,Kinetics of azathioprine metabolism in fresh human blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3832014/),min,28.9,41818,DB01033,Mercaptopurine
,11737747,AUC1-5,"With the intravenously administered 6MPR, the AUC1-5 ranged from 124 to 186 (1.5-fold range, median 145) microM min; only two samples were obtained for the RBC concentration of 6TGN, and were 121 and 273 pmol per 25 mg hemoglobin.",Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737747/),min·μM,124 to 186,42671,DB01033,Mercaptopurine
,11737747,AUC1-5,"With the intravenously administered 6MPR, the AUC1-5 ranged from 124 to 186 (1.5-fold range, median 145) microM min; only two samples were obtained for the RBC concentration of 6TGN, and were 121 and 273 pmol per 25 mg hemoglobin.",Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737747/),min·μM,145,42672,DB01033,Mercaptopurine
,11737747,AUC1-5,"With the intravenously administered 6MPR, the AUC1-5 ranged from 124 to 186 (1.5-fold range, median 145) microM min; only two samples were obtained for the RBC concentration of 6TGN, and were 121 and 273 pmol per 25 mg hemoglobin.",Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737747/),pM,121,42673,DB01033,Mercaptopurine
,11737747,AUC1-5,"With the intravenously administered 6MPR, the AUC1-5 ranged from 124 to 186 (1.5-fold range, median 145) microM min; only two samples were obtained for the RBC concentration of 6TGN, and were 121 and 273 pmol per 25 mg hemoglobin.",Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737747/),pM,273,42674,DB01033,Mercaptopurine
,11737747,AUC1-5,"With the orally administered 6MP, the AUC1-5 ranged from 23 to 65 microM min (2.8-fold range, median 56); the RBC concentration of 6TGN ranged from 18 to 152 pmol per 25 mg hemoglobin (median 75).",Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737747/),min·μM,23 to 65,42675,DB01033,Mercaptopurine
,11737747,AUC1-5,"With the orally administered 6MP, the AUC1-5 ranged from 23 to 65 microM min (2.8-fold range, median 56); the RBC concentration of 6TGN ranged from 18 to 152 pmol per 25 mg hemoglobin (median 75).",Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737747/),,56,42676,DB01033,Mercaptopurine
,18969131,detection limit (,The peak currents of 6-MP are linear to its concentrations ranging from 4.0 x 10(-7) to 1.0 x 10(-4) mol l(-1) with the calculated detection limit (S/N=3) of 2.0 x 10(-7) mol l(-1).,Amperometric determination of 6-mercaptopurine on functionalized multi-wall carbon nanotubes modified electrode by liquid chromatography coupled with microdialysis and its application to pharmacokinetics in rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969131/),[mol] / [l],2.0 x 10(-7),46487,DB01033,Mercaptopurine
,18969131,S/N,The peak currents of 6-MP are linear to its concentrations ranging from 4.0 x 10(-7) to 1.0 x 10(-4) mol l(-1) with the calculated detection limit (S/N=3) of 2.0 x 10(-7) mol l(-1).,Amperometric determination of 6-mercaptopurine on functionalized multi-wall carbon nanotubes modified electrode by liquid chromatography coupled with microdialysis and its application to pharmacokinetics in rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18969131/),[mol] / [l],2.0 x 10(-7),46488,DB01033,Mercaptopurine
,1473196,plasma clearance,There was a significant fall in methotrexate plasma clearance at night (from 5.6 +/- 3 ml/min/kg to 4.7 +/- 2.3 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],5.6,46800,DB01033,Mercaptopurine
,1473196,plasma clearance,There was a significant fall in methotrexate plasma clearance at night (from 5.6 +/- 3 ml/min/kg to 4.7 +/- 2.3 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],4.7,46801,DB01033,Mercaptopurine
,1473196,Renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],17.5,46802,DB01033,Mercaptopurine
,1473196,unbound renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],17.5,46803,DB01033,Mercaptopurine
,1473196,unbound renal clearance,Renal clearance of methotrexate tended to decrease at night and unbound renal clearance decreased significantly (from 17.5 +/- 1.7 ml/min/kg to 8.5 +/- 3.6 ml/min/kg p < 0.05).,Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],8.5,46804,DB01033,Mercaptopurine
,1473196,nonglomerular clearance,"Creatinine clearance did not exhibit diurnal variation, when comparing two 12-h collections, but there was a significant decrease in the nonglomerular clearance of methotrexate (from 14.8 +/- 5.2 to 6 +/- 4 ml/min/kg).",Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],14.8,46805,DB01033,Mercaptopurine
,1473196,nonglomerular clearance,"Creatinine clearance did not exhibit diurnal variation, when comparing two 12-h collections, but there was a significant decrease in the nonglomerular clearance of methotrexate (from 14.8 +/- 5.2 to 6 +/- 4 ml/min/kg).",Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1473196/),[ml] / [kg·min],6,46806,DB01033,Mercaptopurine
,28835099,IC50,HA-GS-MP exhibited obvious targetability and markedly enhanced antitumor effect to OCI/AML-2 human AML cells (IC50 = 16.9 μg 6-MP equiv./mL).,Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28835099/),μg,16.9,53138,DB01033,Mercaptopurine
,28835099,elimination half-life,The pharmacokinetic studies displayed that Cy5-labeled HA-GS-MP had a long circulation time in mice (elimination half-life = 4.37 h).,Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28835099/),h,4.37,53139,DB01033,Mercaptopurine
,9808549,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.63 to 12,59168,DB01033,Mercaptopurine
,9808549,AUC,"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.11 to 8,59169,DB01033,Mercaptopurine
,24800919,relative bioavailability,"Based upon trough levels of the principal active metabolite,6-thioguanine nucleotides (6-TGN),a relative bioavailability of the liquid vs. capsules of 1.01 was found (90% CI 0.86 - 1.20), demonstrating bioequivalence.",A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800919/),,1.01,78755,DB01033,Mercaptopurine
,11147134,partition coefficient,"This prodrug had an improved partition coefficient value of 25.16 compared to 1.22 for free drug, confirming higher lipophilicity.",High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11147134/),,25.16,82399,DB01033,Mercaptopurine
,11147134,partition coefficient,"This prodrug had an improved partition coefficient value of 25.16 compared to 1.22 for free drug, confirming higher lipophilicity.",High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11147134/),,1.22,82400,DB01033,Mercaptopurine
,11147134,half-life,"The pharmacokinetic parameters revealed an increase in half-life, from 61 min to 120 min for the HE liposomes and 296 min for the STHE liposomes.",High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11147134/),min,61,82401,DB01033,Mercaptopurine
,11147134,half-life,"The pharmacokinetic parameters revealed an increase in half-life, from 61 min to 120 min for the HE liposomes and 296 min for the STHE liposomes.",High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11147134/),min,120,82402,DB01033,Mercaptopurine
,11147134,half-life,"The pharmacokinetic parameters revealed an increase in half-life, from 61 min to 120 min for the HE liposomes and 296 min for the STHE liposomes.",High-entrapment liposomes for 6-Mercaptopurine--a prodrug approach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11147134/),min,296,82403,DB01033,Mercaptopurine
,3465489,AUC,"The AUC was between 0 and 6 X 10 ng X min/ml, and AUC normalized to 1 mg/m2 of 6MP was between 0 and 815 ng X min/ml.",Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465489/),[min·ng] / [ml],0 and 6 X 10,83124,DB01033,Mercaptopurine
,3465489,AUC,"The AUC was between 0 and 6 X 10 ng X min/ml, and AUC normalized to 1 mg/m2 of 6MP was between 0 and 815 ng X min/ml.",Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3465489/),[min·ng] / [ml],0 and 815,83125,DB01033,Mercaptopurine
,7874062,stability constant,The stability constant of the soluble complex of 6-MP with sodium benzoate was estimated to be 2-8 M-1 from (1) phase-solubility study and (2) analysis of chemical shifts observed in 1H-NMR.,Improvement of aqueous solubility and rectal absorption of 6-mercaptopurine by addition of sodium benzoate. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874062/),1/[M],2-8,83394,DB01033,Mercaptopurine
,7874062,bioavailability,"Administration of 6-MP with 20% (w/v) sodium benzoate to rat rectum resulted in enhanced absorption and the area under the plasma concentration-time curve was comparable to that obtained by intravenous administration (bioavailability = 100%), while the bioavailability after intrarectal administration of 6-MP with 20% (w/v) sodium hippurate was only 9%.",Improvement of aqueous solubility and rectal absorption of 6-mercaptopurine by addition of sodium benzoate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874062/),%,100,83395,DB01033,Mercaptopurine
,7874062,bioavailability,"Administration of 6-MP with 20% (w/v) sodium benzoate to rat rectum resulted in enhanced absorption and the area under the plasma concentration-time curve was comparable to that obtained by intravenous administration (bioavailability = 100%), while the bioavailability after intrarectal administration of 6-MP with 20% (w/v) sodium hippurate was only 9%.",Improvement of aqueous solubility and rectal absorption of 6-mercaptopurine by addition of sodium benzoate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7874062/),%,9,83396,DB01033,Mercaptopurine
,32867649,flow rate,"The samples were precipitated by methanol with 0.05% formic acid and separated on a Waters Atlantis T3 column (2.1 × 150 mm, 3 μm particles) using 0.1% formic acid in water and methanol at a flow rate of 0.4 mL/min in 4 min.","Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32867649/),[ml] / [min],0.4,94144,DB01033,Mercaptopurine
,32867649,half-life of apparent terminal disposition,"The main parameters, half-life of apparent terminal disposition, maximum observed plasma concentration, total AUC extrapolated to infinity, AUC since initiation of the experiment, mean residence time, distribution volume and clearance were 1.62 ± 0.87 hours, 90.58 ± 60.43 ng/mL, 151.20 ± 94.18 ng·h/mL, 292.06 ± 184.02 ng·h2/mL, 1.90 ± 0.92 hours, 864.08 ± 538.52 L, and 432.75 ± 360.64 L/h for conventional tablets and 1.70 ± 1.10 hours, 84.15 ± 39.50 ng/mL, 147.70 ± 51.80 ng·h/mL, 300.92 ± 124.48 ng·h2/mL, 2.07 ± 0.50 hours, 756.90 ± 324.00 L, and 340.75 ± 125.81 L/h for minitablets, respectively.","Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32867649/),h,1.62,94145,DB01033,Mercaptopurine
,32867649,clearance,"The main parameters, half-life of apparent terminal disposition, maximum observed plasma concentration, total AUC extrapolated to infinity, AUC since initiation of the experiment, mean residence time, distribution volume and clearance were 1.62 ± 0.87 hours, 90.58 ± 60.43 ng/mL, 151.20 ± 94.18 ng·h/mL, 292.06 ± 184.02 ng·h2/mL, 1.90 ± 0.92 hours, 864.08 ± 538.52 L, and 432.75 ± 360.64 L/h for conventional tablets and 1.70 ± 1.10 hours, 84.15 ± 39.50 ng/mL, 147.70 ± 51.80 ng·h/mL, 300.92 ± 124.48 ng·h2/mL, 2.07 ± 0.50 hours, 756.90 ± 324.00 L, and 340.75 ± 125.81 L/h for minitablets, respectively.","Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32867649/),[l] / [h],432.75,94146,DB01033,Mercaptopurine
,32867649,clearance,"The main parameters, half-life of apparent terminal disposition, maximum observed plasma concentration, total AUC extrapolated to infinity, AUC since initiation of the experiment, mean residence time, distribution volume and clearance were 1.62 ± 0.87 hours, 90.58 ± 60.43 ng/mL, 151.20 ± 94.18 ng·h/mL, 292.06 ± 184.02 ng·h2/mL, 1.90 ± 0.92 hours, 864.08 ± 538.52 L, and 432.75 ± 360.64 L/h for conventional tablets and 1.70 ± 1.10 hours, 84.15 ± 39.50 ng/mL, 147.70 ± 51.80 ng·h/mL, 300.92 ± 124.48 ng·h2/mL, 2.07 ± 0.50 hours, 756.90 ± 324.00 L, and 340.75 ± 125.81 L/h for minitablets, respectively.","Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32867649/),[ng] / [ml],84.15,94147,DB01033,Mercaptopurine
,8881811,bioavailabilities,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,7,96426,DB01033,Mercaptopurine
,8881811,bioavailabilities,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,5,96427,DB01033,Mercaptopurine
,8881811,bioavailabilities,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,1,96428,DB01033,Mercaptopurine
,8881811,bioavailability,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,47,96429,DB01033,Mercaptopurine
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],8 and 12,98662,DB01033,Mercaptopurine
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],15 to 20,98663,DB01033,Mercaptopurine
,12742493,late loss,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),mm,0.56,98664,DB01033,Mercaptopurine
,12742493,loss index,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),,0.33,98665,DB01033,Mercaptopurine
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],8.4 to 129.1,100723,DB01033,Mercaptopurine
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],41.4,100724,DB01033,Mercaptopurine
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],37.9 to 172.0,100725,DB01033,Mercaptopurine
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],91.7,100726,DB01033,Mercaptopurine
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.7,100727,DB01033,Mercaptopurine
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.2,100728,DB01033,Mercaptopurine
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],57.9,105531,DB01033,Mercaptopurine
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],68.5,105532,DB01033,Mercaptopurine
,11007112,AUC,The AUC of 6-MP following administration of AZA into the jejunum (67.0 +/- 30.1 ng x hr/ml) was higher compared to the stomach (39.9 +/- 38.1 ng/hr/ml) and cecum (29.2 +/- 10.9 ng x hr/ml).,Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],67.0,107751,DB01033,Mercaptopurine
,11007112,AUC,The AUC of 6-MP following administration of AZA into the jejunum (67.0 +/- 30.1 ng x hr/ml) was higher compared to the stomach (39.9 +/- 38.1 ng/hr/ml) and cecum (29.2 +/- 10.9 ng x hr/ml).,Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[ng] / [h·ml],39.9,107752,DB01033,Mercaptopurine
,11007112,AUC,The AUC of 6-MP following administration of AZA into the jejunum (67.0 +/- 30.1 ng x hr/ml) was higher compared to the stomach (39.9 +/- 38.1 ng/hr/ml) and cecum (29.2 +/- 10.9 ng x hr/ml).,Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],29.2,107753,DB01033,Mercaptopurine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],16.9,107754,DB01033,Mercaptopurine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],52.3,107755,DB01033,Mercaptopurine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],132,107756,DB01033,Mercaptopurine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],22.2,107757,DB01033,Mercaptopurine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],63.4,107758,DB01033,Mercaptopurine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],104,107759,DB01033,Mercaptopurine
,8616954,elimination half-life (t0.5e),"The washout phase of ATG elimination was analysed over 0-300 days; results were well-fitted by a single exponential decay (r2 > 0.95) giving a mean elimination half-life (t0.5e) of 29.8 days (range 14.3-45.0, n = 9).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),d,29.8,113057,DB01033,Mercaptopurine
,8616954,apparent volume of distribution of ATG (Vd),"Data for the first 4 days of treatment were analysed with linear regression to obtain a mean value for the apparent volume of distribution of ATG (Vd) of 0.12 l/kg body weight (range 0.07 to 0.17, n = 5).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),[l] / [body·kg·weight],0.12,113058,DB01033,Mercaptopurine
,43222,terminal half-life,"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),min,41.6,114775,DB01033,Mercaptopurine
,43222,plasma clearance (CLp),"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),[ml] / [kg·min],48.4,114776,DB01033,Mercaptopurine
,43222,volume of distribution (Vdss),"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),[l] / [kg],1.76,114777,DB01033,Mercaptopurine
,12962871,Cmax,A Cmax (30.5+/-13.8 ng/mL) was reached at 2.3+/-1.5 h.,Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],30.5,118331,DB01033,Mercaptopurine
,12962871,trough levels,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],10-20,118332,DB01033,Mercaptopurine
,12962871,exposure,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[h·ng] / [ml],230.6,118333,DB01033,Mercaptopurine
,11320662,peak plasma concentration,"After oral TG (n = 35), the mean (+/- SD) peak plasma concentration was 0.46 +/- 0.68 microM and the AUC ranged from 0.18 to 9.5 microM.h (mean 1.5 microM.h).","Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11320662/),μM,0.46,122373,DB01033,Mercaptopurine
,11320662,AUC,"After oral TG (n = 35), the mean (+/- SD) peak plasma concentration was 0.46 +/- 0.68 microM and the AUC ranged from 0.18 to 9.5 microM.h (mean 1.5 microM.h).","Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11320662/),h·μM,1.5,122374,DB01033,Mercaptopurine
,11320662,steady-state plasma,"Mean steady-state plasma and CSF TG concentrations during CIVI (n = 33) were 2.7 and 0.5 microM, respectively.","Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11320662/),μM,2.7,122375,DB01033,Mercaptopurine
,11320662,TG concentrations,"Mean steady-state plasma and CSF TG concentrations during CIVI (n = 33) were 2.7 and 0.5 microM, respectively.","Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11320662/),μM,0.5,122376,DB01033,Mercaptopurine
,11320662,clearance,The mean (+/- SD) TG clearance was 935 +/- 463 ml/min per m2.,"Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11320662/),[ml] / [m2·min],935,122377,DB01033,Mercaptopurine
excess,3342470,maximum tolerated dose,"A maximum tolerated dose was not defined; however, the projected maximum tolerated dose appears to be in excess of 450 mg/m2.",Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342470/),[mg] / [m2],450,129935,DB01033,Mercaptopurine
,3342470,t 1/2,"The drug is rapidly cleared from plasma (t 1/2 = 3 h), and its volume of distribution is approximately twice that of total body water in children.",Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342470/),h,3,129936,DB01033,Mercaptopurine
,2403095,Elimination half-life,"Elimination half-life of mercaptopurine was significantly longer in the evening than during the day (423 +/- 142 minutes vs 176 +/- 22 minutes, mean +/- SEM).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),min,423,131184,DB01033,Mercaptopurine
,2403095,Elimination half-life,"Elimination half-life of mercaptopurine was significantly longer in the evening than during the day (423 +/- 142 minutes vs 176 +/- 22 minutes, mean +/- SEM).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),min,176,131185,DB01033,Mercaptopurine
,2403095,area under the concentration-time curve (AUC0-infinity),"The area under the concentration-time curve (AUC0-infinity) was significantly larger in the evening (24,713 +/- 3536 ng/mL per minute vs 17,120 +/- 1474 ng/mL per minute).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],"24,713",131186,DB01033,Mercaptopurine
,2403095,area under the concentration-time curve (AUC0-infinity),"The area under the concentration-time curve (AUC0-infinity) was significantly larger in the evening (24,713 +/- 3536 ng/mL per minute vs 17,120 +/- 1474 ng/mL per minute).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],"17,120",131187,DB01033,Mercaptopurine
,2403095,area under the curve,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],7724,131188,DB01033,Mercaptopurine
,2403095,area under the curve,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],2597,131189,DB01033,Mercaptopurine
,2403095,AUC300 min-infinity,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],7724,131190,DB01033,Mercaptopurine
,2403095,AUC300 min-infinity,"These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC300 min-infinity, 7724 +/- 2955 ng/mL per minute in the evening vs 2597 +/- 712 ng/mL per minute during the day).",Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2403095/),[ng] / [min·ml],2597,131191,DB01033,Mercaptopurine
,3153226,steady-state concentrations,"The plasma concentration-time curves of 6MP and 6MPR attained steady-state concentrations of 30-40 microM and 6-12 microM, respectively.",6-Mercaptopurine: total body autoradiograms and plasma concentration-time curves of 6MP and metabolites from marmoset monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153226/),μM,30-40,133995,DB01033,Mercaptopurine
,3153226,steady-state concentrations,"The plasma concentration-time curves of 6MP and 6MPR attained steady-state concentrations of 30-40 microM and 6-12 microM, respectively.",6-Mercaptopurine: total body autoradiograms and plasma concentration-time curves of 6MP and metabolites from marmoset monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153226/),μM,6-12,133996,DB01033,Mercaptopurine
,1623901,AUC,The AUC (538.6 ng.h.ml-1) after the rectal dose of 30 mg/m2 was approximately 1.5-times of that (365.5 ng.h.ml-1) after the oral dose of 87.5 mg/m2.,"Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of ""first-pass"" metabolism. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623901/),[h·ng] / [ml],538.6,138592,DB01033,Mercaptopurine
,1623901,AUC,The AUC (538.6 ng.h.ml-1) after the rectal dose of 30 mg/m2 was approximately 1.5-times of that (365.5 ng.h.ml-1) after the oral dose of 87.5 mg/m2.,"Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of ""first-pass"" metabolism. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623901/),[h·ng] / [ml],365.5,138593,DB01033,Mercaptopurine
,1623901,relative bioavailability,The relative bioavailability of the macrogol suppository compared to the powder was approximately 4.39.,"Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of ""first-pass"" metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623901/),,4.39,138594,DB01033,Mercaptopurine
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],80,139441,DB01033,Mercaptopurine
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],103,139442,DB01033,Mercaptopurine
,9048271,relative bioavailabilities,"The relative bioavailabilities of 6-mercaptopurine after ileocolonic azathioprine administration via delayed-release oral capsules at doses of 200 mg, 400 mg, and 600 mg (means of 15%, 15%, and 12%, respectively) were all significantly less than 100% compared with standard oral azathioprine at a 100-mg dose.",A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048271/),%,15,141789,DB01033,Mercaptopurine
,9048271,relative bioavailabilities,"The relative bioavailabilities of 6-mercaptopurine after ileocolonic azathioprine administration via delayed-release oral capsules at doses of 200 mg, 400 mg, and 600 mg (means of 15%, 15%, and 12%, respectively) were all significantly less than 100% compared with standard oral azathioprine at a 100-mg dose.",A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048271/),%,12,141790,DB01033,Mercaptopurine
less,9048271,relative bioavailabilities,"The relative bioavailabilities of 6-mercaptopurine after ileocolonic azathioprine administration via delayed-release oral capsules at doses of 200 mg, 400 mg, and 600 mg (means of 15%, 15%, and 12%, respectively) were all significantly less than 100% compared with standard oral azathioprine at a 100-mg dose.",A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048271/),%,100,141791,DB01033,Mercaptopurine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],0.25,143668,DB01033,Mercaptopurine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],1.35,143669,DB01033,Mercaptopurine
,15795639,Oral clearance (CL/F),Oral clearance (CL/F) was estimated to be 22.1 L/h (95% confidence intervals [CI] 19.5-24.7 L/h).,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],22.1,143670,DB01033,Mercaptopurine
,15795639,relative oral bioavailability,The relative oral bioavailability of Sandimmune to Neoral was 0.82.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),,0.82,143671,DB01033,Mercaptopurine
less,3564948,half-lives,"In most patients, the peak concentrations were reached 1-2 hours after dose intake and the concentrations then declined with half-lives less than 1 hour.",Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3564948/),h,1,144609,DB01033,Mercaptopurine
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],5.2,149623,DB01033,Mercaptopurine
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],9.4,149624,DB01033,Mercaptopurine
<,14550821,trough levels,"We observed a significantly increased risk of acute rejection at everolimus trough levels <3 ng/ml, which constitutes the lower therapeutic concentration limit when everolimus is used with conventionally dosed cyclosporine.","Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],3,149625,DB01033,Mercaptopurine
,14550821,troughs,Everolimus-related adverse events were manageable up to the highest troughs (22 ng/ml) observed in this population.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],22,149626,DB01033,Mercaptopurine
,2595781,total-body clearance,"Mean +/- SE total-body clearance and elimination half-life were 887 +/- 159 ml/min and 1.4 +/- 0.2 hr, respectively, in the i.v. bolus study, indicating that 6-MP is rapidly cleared from the systemic circulation.",The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595781/),[ml] / [min],887,152842,DB01033,Mercaptopurine
,2595781,elimination half-life,"Mean +/- SE total-body clearance and elimination half-life were 887 +/- 159 ml/min and 1.4 +/- 0.2 hr, respectively, in the i.v. bolus study, indicating that 6-MP is rapidly cleared from the systemic circulation.",The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595781/),h,1.4,152843,DB01033,Mercaptopurine
,8160249,maximal 6-MP plasma concentration (Cmax),"Mean maximal 6-MP plasma concentration (Cmax) was 340 nmol/L (SD = 290), mean time to Cmax (Tmax) was 2 h (SD = 1.8), and mean area under the plasma concentration-time curve (AUC) was 930 nmol/L/h (SD = 770).",Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[nM] / [l],340,152933,DB01033,Mercaptopurine
,8160249,time to Cmax (Tmax),"Mean maximal 6-MP plasma concentration (Cmax) was 340 nmol/L (SD = 290), mean time to Cmax (Tmax) was 2 h (SD = 1.8), and mean area under the plasma concentration-time curve (AUC) was 930 nmol/L/h (SD = 770).",Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),h,2,152934,DB01033,Mercaptopurine
,8160249,area under the plasma concentration-time curve (AUC),"Mean maximal 6-MP plasma concentration (Cmax) was 340 nmol/L (SD = 290), mean time to Cmax (Tmax) was 2 h (SD = 1.8), and mean area under the plasma concentration-time curve (AUC) was 930 nmol/L/h (SD = 770).",Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[nM] / [h·l],930,152935,DB01033,Mercaptopurine
,8160249,fraction,The mean fraction of azathioprine dose excreted as 6-MP in urine was 1.32% (SD = 1.11).,Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),%,1.32,152936,DB01033,Mercaptopurine
,8160249,maxima,In this group of patients the observed 6-TGN levels in RBCs were low; maxima during the observation period ranged from undetectable to 250 pmol/8 x 10(8) RBCs.,Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[pM] / [8],und,152937,DB01033,Mercaptopurine
,8160249,maxima,In this group of patients the observed 6-TGN levels in RBCs were low; maxima during the observation period ranged from undetectable to 250 pmol/8 x 10(8) RBCs.,Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[pM] / [8],250,152938,DB01033,Mercaptopurine
,8366177,steady-state concentrations,"The steady-state concentrations of AZN observed in these patients ranged from 6 to 583 micrograms/L, and the interday coefficients of variation of the concentration in three randomly selected patients were 38%, 12%, and 4.6%.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[μg] / [l],6 to 583,164031,DB01033,Mercaptopurine
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],0.126 to 4,164032,DB01033,Mercaptopurine
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],5 to 12,164033,DB01033,Mercaptopurine
,8366177,alpha,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),1/[h],15.3,164034,DB01033,Mercaptopurine
,8366177,total body clearance,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],8.12,164035,DB01033,Mercaptopurine
,1002367,Elimination,"Elimination during eight hours of haemodialysis amounted to 45%, which is only slightly less than the elimination in the urine of normal persons over a period of 24 hours.",Pharmacokinetics of azathioprine under haemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1002367/),%,45,166071,DB01033,Mercaptopurine
,16261832,elimination half-life,"Plasma concentrations of AZA and its metabolite, 6-MP decreased rapidly from plasma following i.v. administration of AZA, consistent with the short mean elimination half-life of 1.8 minutes.",Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261832/),min,1.8,167208,DB01033,Mercaptopurine
,16261832,Oral bioavailability,"Oral bioavailability of AZA was low, ranging from 1% to 7%.",Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261832/),%,1,167209,DB01033,Mercaptopurine
,16261832,Oral bioavailability,"Oral bioavailability of AZA was low, ranging from 1% to 7%.",Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261832/),%,7,167210,DB01033,Mercaptopurine
exceeding,9815740,steady-state plasma concentration (Css),"A pharmacokinetically guided dose escalation was performed to define the dose rate of TG required to achieve a steady-state plasma concentration (Css) exceeding the target concentration of 1 microM, and then the maximum tolerated duration of infusion of TG at this dose rate was defined.",A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815740/),μM,1,168613,DB01033,Mercaptopurine
,9815740,Css,"The starting dose rate of 10 mg/m2/h administered for 24 h achieved an average Css of 0.9 microM (range, 0.7-1.2 microM).",A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815740/),μM,0.9,168614,DB01033,Mercaptopurine
,9815740,Css,"Therefore, the dose rate was escalated to 20 mg/m2/h, which achieved an average Css of 4.1 microM (range, 1. 0-8.3 microM).",A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815740/),μM,4.1,168615,DB01033,Mercaptopurine
,9815740,clearances,"The TG clearances (derived from model parameters) at the 10- and 20-mg/m2/h dose rates were 987 and 608 ml/min/m2, respectively.",A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815740/),[ml] / [m2·min],987,168616,DB01033,Mercaptopurine
,9815740,clearances,"The TG clearances (derived from model parameters) at the 10- and 20-mg/m2/h dose rates were 987 and 608 ml/min/m2, respectively.",A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815740/),[ml] / [m2·min],608,168617,DB01033,Mercaptopurine
,2615529,time to peak concentration,"Food intake reduced the time to peak concentration both in plasma, from 1.8 h to 1.1 h (P less than 0.01) and in red blood cells, from 1.8 h to 1.3 h (P less than 0.01).",Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2615529/),h,1.8,174119,DB01033,Mercaptopurine
,2615529,time to peak concentration,"Food intake reduced the time to peak concentration both in plasma, from 1.8 h to 1.1 h (P less than 0.01) and in red blood cells, from 1.8 h to 1.3 h (P less than 0.01).",Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2615529/),h,1.1,174120,DB01033,Mercaptopurine
,2615529,time to peak concentration,"Food intake reduced the time to peak concentration both in plasma, from 1.8 h to 1.1 h (P less than 0.01) and in red blood cells, from 1.8 h to 1.3 h (P less than 0.01).",Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2615529/),h,1.3,174121,DB01033,Mercaptopurine
,3456283,steady state E-MTX,The steady state E-MTX varied between 51 and 202 nmol/l erythrocytes.,Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3456283/),[nM] / [l],51 and 202,174128,DB01033,Mercaptopurine
,3456283,terminal half-life,A terminal half-life of 2-5 weeks after discontinuation of the drug showed that the erythrocytes functioned as a slow-changing compartment for MTX.,Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3456283/),weeks,2-5,174129,DB01033,Mercaptopurine
,3470165,peak plasma concentration,"When 6-MP was administered alone, both the peak plasma concentration (15 to 150 ng X ml-1) and the AUC (36 to 340 ng X ml-1 X hr) were highly variable.",The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470165/),[ng] / [ml],15 to 150,175961,DB01033,Mercaptopurine
,3470165,AUC,"When 6-MP was administered alone, both the peak plasma concentration (15 to 150 ng X ml-1) and the AUC (36 to 340 ng X ml-1 X hr) were highly variable.",The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470165/),[h·ng] / [ml],36 to 340,175962,DB01033,Mercaptopurine
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176633,DB01033,Mercaptopurine
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.12,176634,DB01033,Mercaptopurine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.13,176635,DB01033,Mercaptopurine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176636,DB01033,Mercaptopurine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176637,DB01033,Mercaptopurine
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.18,176638,DB01033,Mercaptopurine
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176639,DB01033,Mercaptopurine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176640,DB01033,Mercaptopurine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.10,176641,DB01033,Mercaptopurine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176642,DB01033,Mercaptopurine
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],405,181655,DB01033,Mercaptopurine
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],373,181656,DB01033,Mercaptopurine
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.5,181657,DB01033,Mercaptopurine
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.3,181658,DB01033,Mercaptopurine
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.7,181659,DB01033,Mercaptopurine
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.6,181660,DB01033,Mercaptopurine
,9349933,systemic clearance,"m-2.day-1, the pharmacokinetic parameters were determined after the first i.v. administration of 1 g.m-2 (bolus dose of 0.2 g.m-2 followed by an 8-h infusion of 0.8 g.m-2) in 11 patients: systemic clearance was 23.02 1.h-1, volume of distribution was 0.75 l.kg-1, and elimination half-life was 1.64 h.",Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349933/),[1] / [h],23.02,182682,DB01033,Mercaptopurine
,9349933,volume of distribution,"m-2.day-1, the pharmacokinetic parameters were determined after the first i.v. administration of 1 g.m-2 (bolus dose of 0.2 g.m-2 followed by an 8-h infusion of 0.8 g.m-2) in 11 patients: systemic clearance was 23.02 1.h-1, volume of distribution was 0.75 l.kg-1, and elimination half-life was 1.64 h.",Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349933/),[l] / [kg],0.75,182683,DB01033,Mercaptopurine
,9349933,elimination half-life,"m-2.day-1, the pharmacokinetic parameters were determined after the first i.v. administration of 1 g.m-2 (bolus dose of 0.2 g.m-2 followed by an 8-h infusion of 0.8 g.m-2) in 11 patients: systemic clearance was 23.02 1.h-1, volume of distribution was 0.75 l.kg-1, and elimination half-life was 1.64 h.",Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349933/),h,1.64,182684,DB01033,Mercaptopurine
,9349933,CSF concentration,The CSF concentration was 3.78 mumol.,Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349933/),μM,3.78,182685,DB01033,Mercaptopurine
,9349933,CSF to plasma ratio,"1(-1), 1-6 h after the beginning of infusion (n = 28) and the CSF to plasma ratio was 0.15 (n = 16).",Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349933/),,0.15,182686,DB01033,Mercaptopurine
,16181300,ribonucleotide/tioguanine ratio,Mean 6-methylmercaptopurine ribonucleotide/tioguanine ratio increased significantly from 6.3 at baseline to 11.2.,The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16181300/),,6.3,184215,DB01033,Mercaptopurine
,16181300,ribonucleotide/tioguanine ratio,Mean 6-methylmercaptopurine ribonucleotide/tioguanine ratio increased significantly from 6.3 at baseline to 11.2.,The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16181300/),,11.2,184216,DB01033,Mercaptopurine
,8599862,peak plasma concentration (Cmax),"When 6-MP was given alone, the mean peak plasma concentration (Cmax) and area under the curve (AUC) of 6-MP were 72.5 ng/ml and 225.3 h ng ml(-1).",Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599862/),[ng] / [ml],72.5,189721,DB01033,Mercaptopurine
,8599862,area under the curve (AUC),"When 6-MP was given alone, the mean peak plasma concentration (Cmax) and area under the curve (AUC) of 6-MP were 72.5 ng/ml and 225.3 h ng ml(-1).",Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599862/),[h·ng] / [ml],225.3,189722,DB01033,Mercaptopurine
,40585,plasma half-life,"In a kidney transplant patient given azathioprine, 50 mg i.v., conversion to 6-MP was rapid and the plasma half-life of 6-MP was 36 min.","Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/40585/),min,36,193707,DB01033,Mercaptopurine
,2324584,penetration,Pharmacokinetic study revealed high peaks of Ara-C concentration in plasma (6.2 microM immediately after the end of the infusion) and high degree of its penetration into the CNS (5.6 microM at 3 hr after the end of the infusion) suggesting the effective and perhaps a uniform level of Ara-C is achieved throughout the CNS by this therapy.,[Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324584/),μM,5.6,194604,DB01033,Mercaptopurine
,2526020,peak plasma 6-TU concentration,A peak plasma 6-TU concentration of 710.7 ng/ml was observed at 3.8 h after oral dosing.,Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2526020/),[ng] / [ml],710.7,194659,DB01033,Mercaptopurine
,2526020,peak concentration,6-MP plasma concentrations in the patients were low (mean peak concentration 36.0 ng/ml) and rapidly disappeared within 8 h.,Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2526020/),[ng] / [ml],36.0,194660,DB01033,Mercaptopurine
,1933871,duration of complete responses,The duration of complete responses ranged from 7 to 22 weeks.,"Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1933871/),weeks,7 to 22,197934,DB01033,Mercaptopurine
,9877312,area under the plasma concentration-time curve (AUC),The mean observed area under the plasma concentration-time curve (AUC) was 190+/-140 ng mL(-1) h and the elimination rate constant (Kel) was 1.92+/-1.,6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877312/),[h·ng] / [ml],190,204144,DB01033,Mercaptopurine
,9877312,elimination rate constant (Kel),The mean observed area under the plasma concentration-time curve (AUC) was 190+/-140 ng mL(-1) h and the elimination rate constant (Kel) was 1.92+/-1.,6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877312/),,1.92,204145,DB01033,Mercaptopurine
,2396307,detection limit,The detection limit was 6 nM.,Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396307/),nM,6,207226,DB01033,Mercaptopurine
,2396307,detection limit,A Beckman ODS column was used and the detection limit was 5 nM.,Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396307/),nM,5,207227,DB01033,Mercaptopurine
,4039967,bioavailability,The bioavailability of the drug over 12 hours was 21.67 micrograms/h in the aqueous and 22.22 micrograms/h in the vitreous following subconjunctival administration but only 1.47 and 3.50 micrograms/h respectively following intravenous administration.,Ocular pharmacokinetics of subconjunctivally versus intravenously administered 6-mercaptopurine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039967/),[μg] / [h],21.67,207964,DB01033,Mercaptopurine
,4039967,bioavailability,The bioavailability of the drug over 12 hours was 21.67 micrograms/h in the aqueous and 22.22 micrograms/h in the vitreous following subconjunctival administration but only 1.47 and 3.50 micrograms/h respectively following intravenous administration.,Ocular pharmacokinetics of subconjunctivally versus intravenously administered 6-mercaptopurine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039967/),[μg] / [h],22.22,207965,DB01033,Mercaptopurine
,4039967,bioavailability,The bioavailability of the drug over 12 hours was 21.67 micrograms/h in the aqueous and 22.22 micrograms/h in the vitreous following subconjunctival administration but only 1.47 and 3.50 micrograms/h respectively following intravenous administration.,Ocular pharmacokinetics of subconjunctivally versus intravenously administered 6-mercaptopurine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039967/),[μg] / [h],1.47,207966,DB01033,Mercaptopurine
,4039967,bioavailability,The bioavailability of the drug over 12 hours was 21.67 micrograms/h in the aqueous and 22.22 micrograms/h in the vitreous following subconjunctival administration but only 1.47 and 3.50 micrograms/h respectively following intravenous administration.,Ocular pharmacokinetics of subconjunctivally versus intravenously administered 6-mercaptopurine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039967/),[μg] / [h],3.50,207967,DB01033,Mercaptopurine
,1861221,Cmax,"Overall mean (+/- SD) Cmax and AUC values increased disproportionately (88 +/- 123, to 326 +/- 194, to 653 +/- 344 ng/ml for Cmax, and 147 +/- 180, to 451 +/- 177, to 1291 +/- 415 ng/ml per hour for AUC, respectively) when the dose increased from 50 to 87.5 mg/m2 and then to 175 mg/m2.",Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1861221/),[ng] / [ml],88,209173,DB01033,Mercaptopurine
,1861221,AUC,"Overall mean (+/- SD) Cmax and AUC values increased disproportionately (88 +/- 123, to 326 +/- 194, to 653 +/- 344 ng/ml for Cmax, and 147 +/- 180, to 451 +/- 177, to 1291 +/- 415 ng/ml per hour for AUC, respectively) when the dose increased from 50 to 87.5 mg/m2 and then to 175 mg/m2.",Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1861221/),[ng] / [ml],653,209174,DB01033,Mercaptopurine
,1861221,AUC,"Overall mean (+/- SD) Cmax and AUC values increased disproportionately (88 +/- 123, to 326 +/- 194, to 653 +/- 344 ng/ml for Cmax, and 147 +/- 180, to 451 +/- 177, to 1291 +/- 415 ng/ml per hour for AUC, respectively) when the dose increased from 50 to 87.5 mg/m2 and then to 175 mg/m2.",Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1861221/),[ng] / [h·ml],147,209175,DB01033,Mercaptopurine
,1861221,AUC,"Overall mean (+/- SD) Cmax and AUC values increased disproportionately (88 +/- 123, to 326 +/- 194, to 653 +/- 344 ng/ml for Cmax, and 147 +/- 180, to 451 +/- 177, to 1291 +/- 415 ng/ml per hour for AUC, respectively) when the dose increased from 50 to 87.5 mg/m2 and then to 175 mg/m2.",Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1861221/),[ng] / [h·ml],451,209176,DB01033,Mercaptopurine
,1861221,AUC,"Overall mean (+/- SD) Cmax and AUC values increased disproportionately (88 +/- 123, to 326 +/- 194, to 653 +/- 344 ng/ml for Cmax, and 147 +/- 180, to 451 +/- 177, to 1291 +/- 415 ng/ml per hour for AUC, respectively) when the dose increased from 50 to 87.5 mg/m2 and then to 175 mg/m2.",Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1861221/),[ng] / [h·ml],1291,209177,DB01033,Mercaptopurine
,3153245,time to plasma peak (tmax),"In patients studied in a fasting state, the mean time to plasma peak (tmax) level was 1.2 h, whereas in patient studied after breakfast the mean tmax was 2.3 h.",Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153245/),h,1.2,210490,DB01033,Mercaptopurine
,3153245,tmax,"In patients studied in a fasting state, the mean time to plasma peak (tmax) level was 1.2 h, whereas in patient studied after breakfast the mean tmax was 2.3 h.",Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153245/),h,2.3,210491,DB01033,Mercaptopurine
,3153245,Cmax,"The mean Cmax +/- SD were 0.98 +/- 0.54 microM and 0.63 +/- 0.48 microM, respectively (p less than 0.05).",Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153245/),μM,0.98,210492,DB01033,Mercaptopurine
,3153245,Cmax,"The mean Cmax +/- SD were 0.98 +/- 0.54 microM and 0.63 +/- 0.48 microM, respectively (p less than 0.05).",Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153245/),μM,0.63,210493,DB01033,Mercaptopurine
,3153245,AUC,"The mean 6-MP AUC +/- SD in patients studied in a fasting state and after breakfast were 143 +/- 69 microM min and 105 +/- 68 microM, respectively (p less than 0.01).",Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153245/),min·μM,143,210494,DB01033,Mercaptopurine
,3153245,AUC,"The mean 6-MP AUC +/- SD in patients studied in a fasting state and after breakfast were 143 +/- 69 microM min and 105 +/- 68 microM, respectively (p less than 0.01).",Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3153245/),μM,105,210495,DB01033,Mercaptopurine
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB01033,Mercaptopurine
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB01033,Mercaptopurine
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB01033,Mercaptopurine
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB01033,Mercaptopurine
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB01033,Mercaptopurine
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB01033,Mercaptopurine
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB01033,Mercaptopurine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB01033,Mercaptopurine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB01033,Mercaptopurine
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB01033,Mercaptopurine
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB01033,Mercaptopurine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB01033,Mercaptopurine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB01033,Mercaptopurine
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB01033,Mercaptopurine
,32519032,AUC,Liquid 6MP formulation resulted in a 26% lower AUC (p = 0.02) compared with tablet (median 1215 vs. 1805 h × nmol/l).,Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32519032/),[h·nM] / [l],1215,215067,DB01033,Mercaptopurine
,32519032,AUC,Liquid 6MP formulation resulted in a 26% lower AUC (p = 0.02) compared with tablet (median 1215 vs. 1805 h × nmol/l).,Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32519032/),[h·nM] / [l],1805,215068,DB01033,Mercaptopurine
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),[μg] / [h·ml],52.68,215239,DB01033,Mercaptopurine
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),,4,215240,DB01033,Mercaptopurine
,15089767,half-life time (t1/2),"Pharmacokinetics confirmed a mean maximum plasma arsenic concentration (Cpmax) and a half-life time (t1/2) of 6.9 microm and 3.2 h, respectively, in the therapeutic range.",Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089767/),h,3.2,215252,DB01033,Mercaptopurine
,21323897,AUC,The median AUC per mg 6-TG was 1068 (p.o.) and 7184 (i.v.) pmol·h (8 × 10(8) RBC)(-1) .,Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323897/),(·h·pM,1068,217132,DB01033,Mercaptopurine
,21323897,AUC,The median AUC per mg 6-TG was 1068 (p.o.) and 7184 (i.v.) pmol·h (8 × 10(8) RBC)(-1) .,Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323897/),(·h·pM,7184,217133,DB01033,Mercaptopurine
,30169593,elimination half-life,"All patients discontinuing thiopurines displayed first-order elimination kinetics of 6-TGN, with a median elimination half-life of 6.8 days [interquartile range 5.9-8.4].",Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169593/),d,6.8,221293,DB01033,Mercaptopurine
less,30169593,elimination half-life,"Upon 6MP/azathioprine discontinuation, a 6-TGN elimination half-life of less than 10 days is expected in most patients.",Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169593/),d,10,221294,DB01033,Mercaptopurine
,6132796,"half-life (t1/2, lambda z)","6MP in plasma and CSF had a mean half-life (t1/2, lambda z) of 2.9 hr and an apparent volume of distribution (Vd, lambda z) of 3.00 liter/kg.",Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132796/),h,2.9,221499,DB01033,Mercaptopurine
,6132796,"apparent volume of distribution (Vd, lambda z)","6MP in plasma and CSF had a mean half-life (t1/2, lambda z) of 2.9 hr and an apparent volume of distribution (Vd, lambda z) of 3.00 liter/kg.",Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132796/),[l] / [kg],3.00,221500,DB01033,Mercaptopurine
,6132796,total body clearance,Estimates of total body clearance average 0.731 +/- 0.412 liter/hr/kg and ranged between 0.446 and .1204 liter/hr/kg.,Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following iv bolus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132796/),[l] / [h·kg],0.731,221501,DB01033,Mercaptopurine
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],5.2,222537,DB01033,Mercaptopurine
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],9.4,222538,DB01033,Mercaptopurine
> or =,15575918,trough levels,Biopsy-proven acute rejection (BPAR) was reduced with everolimus trough levels > or =3 ng/mL.,Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],3,222539,DB01033,Mercaptopurine
,4038917,plasma steady-state MP concentration,The mean plasma steady-state MP concentration achieved was 6.9 microM with little interpatient variability seen.,Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4038917/),μM,6.9,229628,DB01033,Mercaptopurine
,4038917,steady-state cerebrospinal fluid:plasma ratio,"The steady-state cerebrospinal fluid:plasma ratio for MP was 0.27, suggesting that this approach may be of value in the treatment of central nervous system cancer.",Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4038917/),,0.27,229629,DB01033,Mercaptopurine
,643124,urinary excretion,"Its urinary excretion is very low (2.5 per cent in 15 hours), 1.7 per cent being eliminated 3 hours after administration.",Pharmacokinetics of butocine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/643124/),%,2.5,236953,DB01033,Mercaptopurine
,643124,urinary excretion,"Its urinary excretion is very low (2.5 per cent in 15 hours), 1.7 per cent being eliminated 3 hours after administration.",Pharmacokinetics of butocine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/643124/),%,1.7,236954,DB01033,Mercaptopurine
,643124,renal clearance,"Its renal clearance is likwise very low, i.e. 1.5 ml/min compared with endogenous creatinine clearance of 81.2 ml/min.",Pharmacokinetics of butocine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/643124/),[ml] / [min],1.5,236955,DB01033,Mercaptopurine
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],29,239826,DB01033,Mercaptopurine
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],18,239827,DB01033,Mercaptopurine
,11264639,clearance,Both were significantly lower compared with a clearance of 37+/-15 mL/h from a previous study of basiliximab with dual therapy (p<0.001).,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],37,239828,DB01033,Mercaptopurine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239829,DB01033,Mercaptopurine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239830,DB01033,Mercaptopurine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239831,DB01033,Mercaptopurine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239832,DB01033,Mercaptopurine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239833,DB01033,Mercaptopurine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239834,DB01033,Mercaptopurine
,1926275,Analytical recovery,Analytical recovery of 6-MP was 90%.,Determination of 6-mercaptopurine in acute lymphoblastic leukemia patients' plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926275/),%,90,240269,DB01033,Mercaptopurine
,12595513,trough,Lowering CsA to low target CsA trough (30 to 70 ng/ml) never led to acute rejection or major renal function deterioration.,Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12595513/),[ng] / [ml],30 to 70,240980,DB01033,Mercaptopurine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,96,248802,DB01033,Mercaptopurine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,97,248803,DB01033,Mercaptopurine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,90,248804,DB01033,Mercaptopurine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,83,248805,DB01033,Mercaptopurine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,74,248806,DB01033,Mercaptopurine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,75,248807,DB01033,Mercaptopurine
,30784100,trough levels,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),[μg] / [ml],1.7,248808,DB01033,Mercaptopurine
,30784100,trough levels,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),[μg] / [ml],5.0,248809,DB01033,Mercaptopurine
,30784100,drug-to-trough ratio,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),,3.9,248810,DB01033,Mercaptopurine
,30784100,drug-to-trough ratio,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),,1.5,248811,DB01033,Mercaptopurine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),[mg] / [l],0.09 to 1.16,251320,DB01033,Mercaptopurine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),pM,133-1733,251321,DB01033,Mercaptopurine
,2341582,peak plasma 6-MP level,The low peak plasma 6-MP level of 73.7 +/- 23.7 ng/mL (mean +/- SD) and the short half-life (t1/2) of 1.9 +/- 0.6 hours suggest rapid conversion of 6-MP to other metabolites.,"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341582/),[ng] / [ml],73.7,252728,DB01033,Mercaptopurine
,2341582,half-life (t1/2),The low peak plasma 6-MP level of 73.7 +/- 23.7 ng/mL (mean +/- SD) and the short half-life (t1/2) of 1.9 +/- 0.6 hours suggest rapid conversion of 6-MP to other metabolites.,"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341582/),h,1.9,252729,DB01033,Mercaptopurine
,2341582,peak plasma 6-TU concentration,A peak plasma 6-TU concentration of 1210 +/- 785 ng/mL was observed at 3.5 +/- 0.6 hours after the AZA dose.,"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341582/),[ng] / [ml],1210,252730,DB01033,Mercaptopurine
,16573602,C0,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],96.2,259396,DB01033,Mercaptopurine
,16573602,C2,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],504,259397,DB01033,Mercaptopurine
,2782561,area under the plasma concentration-time curve (AUC),"Total drug exposure to oral methotrexate, as measured by the mean area under the plasma concentration-time curve (AUC), was 2.75 microM.h following the morning dose and 2.77 microM.h in the evening.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),h·μM,2.75,260646,DB01033,Mercaptopurine
,2782561,area under the plasma concentration-time curve (AUC),"Total drug exposure to oral methotrexate, as measured by the mean area under the plasma concentration-time curve (AUC), was 2.75 microM.h following the morning dose and 2.77 microM.h in the evening.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),h·μM,2.77,260647,DB01033,Mercaptopurine
,2782561,AUC,"For 6-mercaptopurine, the mean morning AUC (198 ng.h/ml) was higher than that following the evening dose (167 ng.h/ml) (p greater than 0.05); but compared to the wide interpatient variability observed with this drug, this 20% difference is not likely to be clinically significant.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),[h·ng] / [ml],198,260648,DB01033,Mercaptopurine
,2782561,AUC,"For 6-mercaptopurine, the mean morning AUC (198 ng.h/ml) was higher than that following the evening dose (167 ng.h/ml) (p greater than 0.05); but compared to the wide interpatient variability observed with this drug, this 20% difference is not likely to be clinically significant.",Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2782561/),[h·ng] / [ml],167,260649,DB01033,Mercaptopurine
,9776421,Elimination half-life,Elimination half-life was longer in the 9 cyclosporine-treated subjects (108.0+/-13.6 min) than in the other nine (71.2+/-8.3 min; p <0.02).,Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776421/),min,108.0,262698,DB01033,Mercaptopurine
,9776421,Elimination half-life,Elimination half-life was longer in the 9 cyclosporine-treated subjects (108.0+/-13.6 min) than in the other nine (71.2+/-8.3 min; p <0.02).,Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776421/),min,71.2,262699,DB01033,Mercaptopurine
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB01033,Mercaptopurine
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB01033,Mercaptopurine
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB01033,Mercaptopurine
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB01033,Mercaptopurine
,8852717,C.V.,"The limit of quantification was at 2.5 +/- 0.256 ng (C.V. 10.25%), thus allowing drug monitoring in long-term patients.",High-performance liquid chromatographic assay for the measurement of azathioprine in human serum samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852717/),%,10.25,271894,DB01033,Mercaptopurine
